KRAS and non-small cell lung carcinoma: The low frequency of metastatic KRAS/TP53 hotspot-mutant NSCLC in this cohort may not reflect the real picture of NSCLC patients in society, as physicians requested genomic profiling only for patients with sufficient bone marrow, liver, and kidney function as well as decent performance function (about three quarters of the patients had an Eastern Cooperative Oncology Group score of 1 or better).